Boehringer Ingelheim
-
Boehringer Ingelheim partners with Aster DM Healthcare to transform CRM care in UAE
Aster DM Healthcare was represented by Rahul Kadavakolu, Group Chief Marketing Officer, while Boehringer Ingelheim was represented by Ousama Alhaj, General Manager and Head of Human Pharma for the Near East and UAE, alongside Ghaleb Al Ahdab, Head of Public and Government Affairs for the Near East and UAE.
-
Hamad Medical Corporation signs MoU with Boehringer Ingelheim to transform Qatar’s clinical research
Under the partnership, the two organizations will work together to enhance HMC’s Clinical Trials Unit (CTU), strengthen research expertise, and develop initiatives that support the continued growth of Qatar’s healthcare sector.
-
Japan’s MHLW approves Boehringer’s Jascayd as first PDE4B inhibitor for lung fibrosis
Jascayd acts as the first phosphodiesterase 4B (PDE4B) inhibitor approved for these indications, offering both antifibrotic and immunomodulatory activity.
-
Boehringer Ingelheim opens USD202.7M AI hub in London to accelerate drug discovery
The new Computational Innovation site will focus on using advanced data science to better understand disease biology and identify biological mechanisms with a higher likelihood of success in drug development.
-
Boehringer Ingelheim partners with Zai Lab for dual-targeting lung cancer trial
The Phase Ib/II trial will assess safety, tolerability, and early signs of clinical activity. Researchers will combine Boehringer Ingelheim’s investigational T-cell engager, obrixtamig, with Zai Lab’s antibody-drug conjugate (ADC), zocilurtatug pelitecan (zoci).
-
Boehringer Ingelheim inks USD500M immunology deal with Sitryx to target autoimmune disease
Sitryx stands to receive development, regulatory, and commercialization milestone payments exceeding USD 500 million, alongside tiered royalties on future sales if any drug from the partnership reaches the market.
-
Boehringer Ingelheim appoints Meenal Gauri as Managing Director for India region
She will oversee the pharmaceutical company’s operations across India, Bangladesh, Nepal, Sri Lanka, and Maldives while joining the Board of Boehringer Ingelheim India.